

Indy Sandaradura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6920929/publications.pdf>

Version: 2024-02-01

41
papers

1,226
citations

643344

15
h-index

445137

33
g-index

43
all docs

43
docs citations

43
times ranked

1889
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 669-679.	1.1	23
2	Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients. <i>Infectious Diseases and Therapy</i> , 2022, 11, 201-216.	1.8	6
3	Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 121-132.	1.0	18
4	Multidrug-resistant OXA-48/CTX-M-15 <i>Klebsiella pneumoniae</i> cluster in a COVID-19 intensive care unit: salient lessons for infection prevention and control during the COVID-19 pandemic. <i>Journal of Hospital Infection</i> , 2022, 126, 64-69.	1.4	3
5	C/MIC > 4: A Potential Instrument to Predict the Efficacy of Meropenem. <i>Antibiotics</i> , 2022, 11, 670.	1.5	1
6	Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1521-1528.	1.3	5
7	Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	6
8	Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	15
9	Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections. <i>Clinical Pharmacokinetics</i> , 2021, 60, 711-725.	1.6	23
10	Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4221-4229.	1.1	16
11	Reply to Van Daele et al., "Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets". <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	1
12	A Large Sample Retrospective Study on the Distinction of Voriconazole Concentration in Asian Patients from Different Clinical Departments. <i>Pharmaceuticals</i> , 2021, 14, 1239.	1.7	5
13	Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children. <i>Antibiotics</i> , 2021, 10, 1542.	1.5	8
14	Phage therapy for severe bacterial infections: a narrative review. <i>Medical Journal of Australia</i> , 2020, 212, 279-285.	0.8	37
15	The Antibody Response to SARS-CoV-2 Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa387.	0.4	45
16	Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106180.	1.1	17
17	Clinical evaluation of SARS-CoV-2 point-of-care antibody tests. <i>Pathology</i> , 2020, 52, 783-789.	0.3	9
18	Safety of bacteriophage therapy in severe <i>Staphylococcus aureus</i> infection. <i>Nature Microbiology</i> , 2020, 5, 465-472.	5.9	258

#	ARTICLE	IF	CITATIONS
19	A close shave? Performance of P2/N95 respirators in healthcare workers with facial hair: results of the BEARDS (BENchmarking Adequate Respiratory Defences) study. <i>Journal of Hospital Infection</i> , 2020, 104, 529-533.	1.4	47
20	An evaluation of the userâ€ƒfriendliness of Bayesian forecasting programs in a clinical setting. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2436-2441.	1.1	27
21	Influenza: overview on prevention and therapy. <i>Australian Prescriber</i> , 2019, 42, 51.	0.5	9
22	Pathology at the clinical bedside: Bringing digital microbiology to the intensive care unit. <i>Pathology</i> , 2019, 51, S70.	0.3	0
23	Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 240-244.	1.1	10
24	Flucloxacillin therapeutic drug monitoring in a neonate on extracorporeal membrane oxygenation. <i>Journal of Paediatrics and Child Health</i> , 2019, 55, 246-247.	0.4	1
25	New Formulation Suba-Itraconazole Prophylaxis in Patients with Haematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S335-S336.	2.0	1
26	Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1017-1027.	1.6	17
27	1139. Novel Formulation SUBA-Itraconazole Prophylaxis in Patients With Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow-up Survival Data. <i>Open Forum Infectious Diseases</i> , 2018, 5, S342-S342.	0.4	1
28	Barriers and facilitators of appropriate vancomycin use: prescribing context is key. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1523-1529.	0.8	15
29	An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric Î²-lactam therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2171-2175.	1.3	22
30	Establishment of an AUC _{0â€ƒ24} Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	75
31	Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3414-3419.	1.3	43
32	Too much of a good thing: a retrospective study of Î²-lactam concentrationâ€ƒtoxicity relationships. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2891-2897.	1.3	188
33	Redesign of computerized decision support to improve antimicrobial prescribing. <i>Applied Clinical Informatics</i> , 2017, 08, 949-963.	0.8	24
34	<i>Angiostrongylus cantonensis</i> : a review of its distribution, molecular biology and clinical significance as a human pathogen. <i>Parasitology</i> , 2016, 143, 1087-1118.	0.7	162
35	Documenting antibiotic use in transition from intensive care unit to wards. <i>Journal of Pharmacy Practice and Research</i> , 2016, 46, 91-92.	0.5	1
36	Posaconazole Plasma Concentrations during Intravenous to Oral Tablet Crossover: Are Variations Due to Distribution and Metabolism Rather Than Absorption?. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S475-S476.	2.0	1

#	ARTICLE	IF	CITATIONS
37	Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2413-2414.	1.3	8
38	Molecular Epidemiology of Imported Cases of Leishmaniasis in Australia from 2008 to 2014. <i>PLoS ONE</i> , 2015, 10, e0119212.	1.1	17
39	Cardiac cysticercosis. <i>International Journal of Cardiology</i> , 2013, 168, 557-559.	0.8	11
40	Update on antimicrobial resistance: mechanisms, methods and practice. <i>Pathology</i> , 2012, 44, S48.	0.3	0
41	Disability after encephalitis: development and validation of a new outcome score. <i>Bulletin of the World Health Organization</i> , 2010, 88, 584-592.	1.5	50